Table 2.

Multivariate-adjusted ovarian cancer RR (95% CI) by tertile of hemoglobin adducts of acrylamide and glycidamide in the NHS and NHSII

CasesT1T2T3P trenda
Total adducts (acrylamide and glycidamide)
All
Cases/controls94/17084/17685/169
Cut-pointsb (pmol/g Hb)0–99>99–134.1>134.1
RRc2631.000.83 (0.56–1.24)0.79 (0.50–1.24)0.08
Serousd1561.000.93 (0.59–1.46)0.82 (0.49–1.37)Phete
Nonserousd791.000.96 (0.53–1.75)0.69 (0.34–1.40)0.86
Nonsmokers
Cases/controls82/15275/15773/151
Cut-pointsf (pmol/g Hb)0–95.7>95.8–124.2>124.2
RRg2301.000.84 (0.56–1.26)0.84 (0.55–1.27)0.13
Acrylamide
All
Cases/controls92/17184/17587/169
Cut-pointsb (pmol/g Hb)0–54.6>54.6–73.2>73.2
RRc2631.000.86 (0.58–1.26)0.89 (0.57–1.39)0.05
Serousd1561.000.97 (0.62–1.54)0.89 (0.54–1.49)Phete
Nonserousd791.000.79 (0.42–1.46)0.83 (0.42–1.63)0.83
Nonsmokers
Cases/controls80/15275/15775/151
Cut-pointsf (pmol/g Hb)0–52.3>53.4–68.5>68.5
RRg2301.000.87 (0.58–1.31)0.85 (0.56–1.30)0.06
Glycidamide
All
Cases/controls82/171105/17476/170
Cut-pointsb (pmol/g Hb)0–41.9>41.9–61.6>61.6
RRc2631.001.29 (0.88–1.90)0.80 (0.49–1.29)0.19
Serousd1561.001.08 (0.69–1.68)0.71 (0.42–1.21)Phete
Nonserousd791.001.72 (0.94–3.17)0.87 (0.41–1.83)0.37
Nonsmokers
Cases/controls75/15393/15662/151
Cut-pointsf (pmol/g Hb)0–40.2>40.2–58>58
RRg2301.001.14 (0.77–1.71)0.80 (0.52–1.23)0.36
  • aLinear trend test across log-transformed biomarker levels using the Wald test determined the P-trend.

  • bCut-points obtained from controls.

  • cConditioning on matching factors and adjusting for height, family history of ovarian cancer, tubal ligation, OC use, BMI, parous, number of additional children, average number of alcohol drinks per week, smoking, physical activity, and caffeine intake.

  • dPolytomous logistic regression adjusting for matching factors and the same covariates as listed above plus assay batch, allowing age at blood draw and parity to vary between serous and nonserous cases.

  • eLikelihood ratio test comparing full model (allowing the exposure association to vary by histology) to the reduced model that held exposure estimates constant across tumor subtype.

  • fCut-points obtained from controls who were nonsmokers.

  • gUnconditional logistic regression adjusting for matching factors and the same covariates listed above plus assay batch.